Page 8 - Molecular Testing News Today

Pleural disease encompasses various conditions affecting the pleura, the thin membrane surrounding the lungs. Pleurisy involves inflammation of the pleura,...

The test will be covered under the existing LCD for molecular testing for solid organ transplant rejection in surveillance monitoring.

Represents third covered indication for Prospera ... -Today at 09:07 am- MarketScreener

CareDx Welcomes Open Process to Gain Transplant Community Feedback on Critical Medicare Coverage Decision ... -August 11, 2023 at 07:01 am- MarketScreener

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.